May 28, 2026 | GSK/Ionis Bepirovirsen Achieves 19% Functional Cure in Hepatitis B episode artwork

EPISODE · May 29, 2026 · 10 MIN

May 28, 2026 | GSK/Ionis Bepirovirsen Achieves 19% Functional Cure in Hepatitis B

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

Bepirovirsen hits 19% functional cure rate in Phase 3 chronic HBV trials — a first for a disease affecting 300 million. Plus Spero's 245% surge on tebipenem, AstraZeneca's Imfinzi NMIBC approval, CVS restoring Lilly obesity drug coverage, BridgeBio LGMD data, Kardigan IPO plans, and ASCO 2026 abstracts drop.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, bepirovirsen, GSK, Ionis, hepatitis B, functional cure, Spero Therapeutics, tebipenem, oral carbapenem, cUTI, CVS, Eli Lilly, Zepbound, Foundayo, obesity drugs, AstraZeneca, Imfinzi, durvalumab, bladder cancer, NMIBC, BridgeBio, BBP-418, LGMD, muscular dystrophy, Kardigan Therapeutics, MyoKardia, Secretome Therapeutics, Duchenne, ASCO 2026, Trump drug pricing, MFN, Akeso, Novo Nordisk, Merck, BioNTech, Moderna, Lilly, Sanofi, BMS 

Bepirovirsen hits 19% functional cure rate in Phase 3 chronic HBV trials — a first for a disease affecting 300 million. Plus Spero's 245% surge on tebipenem, AstraZeneca's Imfinzi NMIBC approval, CVS restoring Lilly obesity drug coverage, BridgeBio LGMD data, Kardigan IPO plans, and ASCO 2026 abstracts drop.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, bepirovirsen, GSK, Ionis, hepatitis B, functional cure, Spero Therapeutics, tebipenem, oral carbapenem, cUTI, CVS, Eli Lilly, Zepbound, Foundayo, obesity drugs, AstraZeneca, Imfinzi, durvalumab, bladder cancer, NMIBC, BridgeBio, BBP-418, LGMD, muscular dystrophy, Kardigan Therapeutics, MyoKardia, Secretome Therapeutics, Duchenne, ASCO 2026, Trump drug pricing, MFN, Akeso, Novo Nordisk, Merck, BioNTech, Moderna, Lilly, Sanofi, BMS

NOW PLAYING

May 28, 2026 | GSK/Ionis Bepirovirsen Achieves 19% Functional Cure in Hepatitis B

0:00 10:34

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 10 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on May 29, 2026.

What is this episode about?

Bepirovirsen hits 19% functional cure rate in Phase 3 chronic HBV trials — a first for a disease affecting 300 million. Plus Spero's 245% surge on tebipenem, AstraZeneca's Imfinzi NMIBC approval, CVS restoring Lilly obesity drug coverage, BridgeBio...

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!